Retrospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Mar 7, 2015; 21(9): 2746-2753
Published online Mar 7, 2015. doi: 10.3748/wjg.v21.i9.2746
Table 1 Baseline clinical characteristics of the study patients
VariableTotal (n = 59)TDF (n = 28)LAM + ADV (n = 31)P value
Age1 (yr)36.36 ± 10.14 (18-58)35.81 ± 9.85 (18-56)32.06 ± 8.36 (21-58)0.656
Male gender, n (%)54 (91.52)26 (92.9)28 (90.32)0.698
Initial ALT1 (U/L)101.54 ± 26.1498.25 ± 28.16104.94 ± 24.330.542
Serum creatinine1 (μmol/L)94.61 ± 18.9289.85 ± 18.8398.82 ± 16.650.340
Serum phosphorus1 (mmol/L)1.14 ± 0.231.14 ± 0.221.16 ± 0.250.740
HBeAg positivity, n (%)52 (88.14)25 (89.29)27 (87.10)1.000
Cirrhosis, n (%)5 (8.49)2 (7.14)3 (9.68)0.932
Serum HBV DNA1 (log10 copyies/mL)5.08 ± 1.115.13 ± 1.085.04 ± 31.160.639
Prior LAM + ADV therapy (mo)
Median111112
Range (mix-max)6-246-228-24
LAM resistance mutation, n (%)47 (79.66)23 (82.14)24 (77.42)0.653
rtM204I/V15 (25.42)69
rtL180M4 (6.78)22
rtM204I/V + rtL180M28 (47.46)1513
ADV resistance mutation, n (%)3 (5.08)1 (3.57)2 (6.45)1.000
rtN236T01
rtA181T10
rtA181V01
Unknown245